Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

4-amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing compounds having high potency against raltegravir-resistant integrase mutants of HIV-1.

Journal of medicinal chemistry - 26 Jun 2014

Zhao Xue Zhi, Smith Steven J, Métifiot Mathieu, Marchand Christophe, Boyer Paul L, Pommier Yves, Hughes Stephen H, Burke Terrence R

Abstract excerpt

There are currently three HIV-1 integrase (IN) strand transfer inhibitors (INSTIs) approved by the FDA for the treatment of AIDS. However, the emergence of drug-resistant mutants emphasizes the need to develop additional agents that have improved efficacies against the existent resistant mutants. As reported herein, we modified our recently disclosed 1-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamides IN...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to HIV Integrase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Integrase Inhibitors

Share to Naphthyridines

Share to Pyrrolidinones

Share to Raltegravir Potassium

Share to Stereoisomerism

Share to Virus Replication

Source

Open in PubMed Open full text

Identifiers

PMID: 24901667
DOI: 10.1021/jm5001908
PMCID: PMC4216207

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

4-amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing compounds having high potency against raltegravir-resistant integrase mutants of HIV-1.PMID 24901667Read ↗

Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.Semantic proximity Read ↗

Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.Semantic proximity Read ↗

HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase MutantsSemantic proximity Read ↗

Resistance to Integrase InhibitorsSemantic proximity Read ↗

3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase.Semantic proximity Read ↗

HIV-1 Integrase Inhibitors with Modifications That Affect Their Potencies against Drug Resistant Integrase Mutants.Semantic proximity Read ↗

Recent Advances in the Discovery of Small-Molecule Inhibitors of HIV-1 IntegraseSemantic proximity Read ↗

Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137)Semantic proximity Read ↗

Development of the next generation of HIV-1 integrase inhibitors: pyrazolone as a novel inhibitor scaffold.Semantic proximity Read ↗

HIV-1 Integrase Inhibitors That Are Broadly Effective against Drug-Resistant Mutants.Semantic proximity Read ↗

MK-0536 Inhibits HIV-1 Integrases Resistant to RaltegravirSemantic proximity Read ↗

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.